Nephrology Fellow at Mayo Clinic Rochester | NSMC 2023 |
Rochester, MN
Joined February 2021
- Tweets156
- Following1.1K
- Followers359
- Likes3.6K
Arjun Mohan retweeted
Kidney biopsy findings in a patient treated with complement inhibitor-pegcetacoplan. First one for me.
Glomeruli appear and vacuolated and washed out. The vacuoles are most prominent in the podocytes.
The interstitium also contains vacuolated cells.
Glomeruli appear non proliferative and were negative for Ig and C3 on Immunofluorescence.
However, there was extensive global glomerulosclerosis and tubular atrophy and interstitial fibrosis.
Arjun Mohan retweeted
Drug-Induced Thrombotic Microangiopathy in Cancer
Can Kidney Biopsy Help Unravel This Highly Heterogeneous Pathologic Entity? 👇🏽Check out this editorial @MBarbarini
#onconephrology
Drug-Induced Thrombotic Microangiopathy in Cancer
@Mbarbarini @HerrmannMd @asnpublications
ovid.com/jnls/kidney360/full…
Arjun Mohan retweeted
Bispecific Antibodies for Glomerular Diseases: Are We Ready for Prime Time? ovid.com/jnls/jasn/fulltext/… @ISGDtweets @asnpublications @GlomCon @SabineKaram6 @BoudhabhayI
Arjun Mohan retweeted
Spatial Transcriptomics and Mechanisms of Immune Checkpoint Inhibitor-Associated Interstitial Nephritis - Kidney International Reports kireports.org/article/S2468-…
@EladSharonMD @rc_oncneph @IwijnDeVlaminck
Arjun Mohan retweeted
Great collaborative effort by @PaulHannaMD @gudnephron @kdjhaveri @iamnephrologist @rc_oncneph @kidneymo @ShrutiGkidney @renalmyeloma and many others!
Now online in @NDTsocial
Nephrotoxicity of Non-Platinum Agents and Miscellaneous Nephrotoxic Drugs
🧐Knowing these kidney toxicity profiles is critical to maximize the oncologic benefit while preserving kidney function.
▶️academic.oup.com/ndt/article…
Arjun Mohan retweeted
Fernando Fervenza puts on a very Fernando performance in this deep dive into obinutuzumab for idiopathic membranous nephropathy and the MAJESTY trial @FreelyFiltered
nephjc.com/freelyfiltered/20…
Arjun Mohan retweeted
Immune Checkpoint Inhibitor Therapy of Malignancy in Kidney Transplant Recipients: Analysis of Real-world Outcomes
ovid.com/jnls/transplantatio…
Arjun Mohan retweeted
My 2026 Update on Diagnosis, Risk Stratification, and Treatment of Myeloma is out! #OpenAccess
It’s current including all recent advances in immunotherapy. Managed to squeeze in iberdomide approval from 6 days ago! Bookmark!
onlinelibrary.wiley.com/doi/…
Arjun Mohan retweeted
Looking forward to it ! See you in September! #onconephrology
@onconephsociety @MayoClinicNeph @OncnephBoston26
🐭 Can mice help us understand immune-mediated kidney injury?
Sandra Herrmann @HerrmannMd explores how murine models are shaping our understanding of acute interstitial nephritis.
#Onconephrology
@onconephsociety @onconeph @rc_oncneph @ShrutiGkidney
Arjun Mohan retweeted
In this article we compared the renal outcome of AAV pts w renal involvement (eGFR <30 ml/min) treated with RTX alone vs. RTX + avacopan. No difference in renal outcomes btw the 2 groups but less exposure to steroids in those receiving avacopan.
kireports.org/article/S2468-…
Arjun Mohan retweeted
Excited to share our new publication in Kidney International Reports! 👏🏽🙌🏼🔥🎉@KIReports
Congratulations to my friend and colleague Dr. Cristián Juanet, who led this important study evaluating rituximab with or without avacopan in ANCA-associated vasculitis with severe renal involvement, under the mentorship of Dr. Ladan Zand @LadanZand and Dr. Fernando Fervenza @fervenzaf
Grateful to have contributed to this work and especially thankful to the Mayo Clinic Nephrology Fellowship @MayoClinicNeph for the mentorship, collaboration, and opportunities to grow as a clinician and researcher. @MayoClinic
doi.org/10.1016/j.ekir.2026.…
Arjun Mohan retweeted
Don’t forget to register for our very first Mayo Clinic GN course happening Oct 2nd and 3rd! We have an amazing lineup of expert with many case-based sessions. @fervenzaf @LeticiaRolonMD @SethiRenalPath
Link below:
ce.mayo.edu/nephrology/conte…
Arjun Mohan retweeted
😊👏👏 Prof. Fernando Fervenza presenting the Phase III MAJESTY Trial at the Late Breaking Clinical Trials session at #ERA2026. @fervenzaf @ERAkidney
#ERA26
Presented at #ERA26:
In this 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. Full phase 3 MAJESTY trial results: nej.md/4dZsVPD
@ERAkidney
ALT A line graph from an article published in the New England Journal of Medicine compares obinutuzumab and tacrolimus in treating primary membranous nephropathy over 104 weeks. The y-axis represents the percentage of patients relapse‑free, while the x-axis represents weeks. The graph shows two lines, one for obinutuzumab and another for tacrolimus. The image mentions the European Renal Association Congress at the top.
Arjun Mohan retweeted
😊👏👏 Outstanding presentation by our world-renowned consultant, Fernando Fervenza, at the Late Breaking Clinical Trials session during the 63rd ERA Congress in Glasgow. #ERA2026 #ERA26 European Renal Association @ERAkidney @fervenzaf at Late Breaking Clinical Trial Session
The Phase III MAJESTY Trial compared obinutuzumab versus tacrolimus in primary membranous nephropathy, addressing a critical unmet need in glomerular disease. It was inspiring to see a packed auditorium and tremendous engagement as these landmark results were presented to the international nephrology community.
👏👏🎉🙂 Congratulations to Dr. Fervenza and the entire MAJESTY Trial team for advancing the field and bringing new hope to patients with primary membranous nephropathy. Exciting times ahead for precision therapies in glomerular diseases.
We, at Mayo Clinic Nephrology, are proud to see Dr. Fervenza continue to lead groundbreaking clinical research that advances patient care and shapes the future of glomerular disease treatment worldwide. @MayoClinicNeph @HerrmannMd
#ERA2026 #Nephrology #GlomerularDisease #MembranousNephropathy #MAJESTYTrial #ClinicalTrials #KidneyDisease #MayoClinic #ERACongress #KidneyResearch
Arjun Mohan retweeted
😊😃🙏🏻 Happy to share that our American Society of Nephrology article, “AI in Nephrology Hands-On Primer: Practical Applications and Clinical Integration,” has been published in ASN Kidney News (May 2026).
This article highlights key insights and practical lessons from the ASN AI in Nephrology Hands-On Primer Workshop held in New York, focusing on real-world applications of AI in kidney care, clinical workflow integration, education, and responsible implementation.
The integration of AI into nephrology is no longer theoretical. The key challenge now is how to use these tools effectively, safely, and thoughtfully in clinical practice.
Grateful to collaborate with Noppawit Aiumtrakul, Arjunmohan Mohan, and Harshil A. Fichadiya, with me, Wisit Cheungpasitporn, 😊🙏🏻 thankful to ASN Kidney News and the ASN AI community for advancing education and innovation in this rapidly evolving field.
@NoppawitMD @Arjun_Mohan1 @MayoClinicNeph
📖 ASN Kidney News, Volume 18, Issue 5 (May 2026)
DOI: 10.62716/kn.003482026
New in #ASNKidneyNews: "AI in Nephrology Hands-On Primer: Practical Applications and Clinical Integration." Read what experts in the field have to say after taking part in an innovative workshop: kidney.pub/KN1805-08
Arjun Mohan retweeted
So proud of our Mayo Clinic Nephrology fellowship graduates as they complete this important chapter and begin the next stage of their careers.
Arjun Mohan retweeted
AI in Nephrology Hands-On Primer: Practical Applications and Clinical Integration
@asnpublications @ASNKidney
@NoppawitMD @Arjun_Mohan1 @wisit661
kidneynews.org/view/journals…
Arjun Mohan retweeted
RAAS blockade in the kidney Life-Cycle: Treatment Standard
doi.org/10.1093/ndt/gfag090
